Author's response to reviews

Title: Tuberculous peritonitis in pregnancy: a case report

Authors:

mounia lahbabi (m.lahbabi@yahoo.fr)
jihane brini (j.brini@yahoo.fr)
khalid massaoudi (k.khalid@yahoo.fr)

Version: 2 Date: 1 October 2013

Author's response to reviews: see over
Title: Tuberculous peritonitis in pregnancy: a case report

Thank you very much for your comments+++++

1. The Ethnicity of the patient was included in the Abstract and Case presentation sections.
2. The description of the patient’s gender was changed from ‘woman’ to ‘female’.
3. A list of abbreviations used in the manuscript and their meanings was included after the Conclusions section.
4. The Figure Legends section was repositioned after the References list.

Reviewer: Athanasios Marinis

Thank you very much for your comments+++++

Peritoneal laparoscopy was replaced by diagnostic laparoscopy, Four days was replaced by by four days and in discussion section exudate was replaced by exudates as requested.

Reviewer: Mehmet Bektas

Thank you very much for your comments+++++

1. Did they see any adverse effect of antituberculosis therapy? in this case the treatment was well tolerated during pregnancy and after delivery and we haven’t seen any adverse effect of antituberculosis therapy neither in the mother nor in the neonate.
2. Did you go on the treatment of antituberculosis therapy after delivery? during pregnancy (22 weeks' gestation) and after delivery. Duration of treatment was 6 months.
3. Is antituberculosis therapy safely during the pregnancy? antituberculosis therapy is safely during the pregnancy. the initial regimen should be isoniazid, rifampin, and ethambutol for at least 6 months. Although teratogenicity data for pyrazinamide are limited, it is probably safe to use in pregnancy.